◀ Anchor ▶
Among the major corona vaccines, AstraZeneca, made in the UK, is the easiest to administer and easy to get mass vaccination.
Korea has also completed a purchase contract for 10 million people.
The European Union has approved the use of this vaccine.
It means there are no problems.
However, in France there is a controversy over the effectiveness of this vaccine.
Reporter Yoon Hyo-jung covered what you were talking about.
◀ Report ▶
The European Commission has officially approved the conditional sale of AstraZeneca’s corona vaccine.
There are also observations that there will be an age limit, but it has been licensed to everyone over 18 years of age.
[에머 쿡/유럽의약품청장]
“It was not limited to those under the age of 55. It was decided based on the experimental evidence, safety, and immunity for the elderly.”
The third vaccine after Pfizer and Modena.
Due to the shortage of vaccine supply, Europe, which had been struggling with pharmaceutical companies, has secured an additional 400 million doses.
The controversy reignited in the mouth of French President Macron just before the announcement of approval.
President Macron reaffirmed that the AstraZeneca vaccine has little effect on people over 65 and is not recommended by people in their 60s.
While France is scheduled to announce the approval of its own health authorities early next week, Korea is also starting to deliberate on approval of the AstraZeneca vaccine tomorrow.
The safety of the vaccine is reviewed as a whole, but the key is whether it works for people over 65.
In Korea, the purchase contract for 10 million AstraZeneca vaccines has been completed, and vaccination will start from next month when screening and supply are conducted as scheduled.
Among these, the final clinical results of Johnson & Johnson vaccine, a US pharmaceutical company, were also released.
Although it is low compared to Pfizer and Modena with an average of 66 percent prevention, experts have rated it as strong enough as a vaccine.
[앤서니 파우치/미국알레르기·전염병연구소장]
“The important thing is that (the Johnson & Johnson vaccine) is quite effective in preventing severe COVID-19. None of the people who got the vaccine were hospitalized or died.”
Johnson & Johnson plans to apply for emergency use approval from the FDA next week, and unlike other vaccines, it is said that it has a preventive effect even if it is given once.
This is Hyojeong Yoon of MBC News.
(Video editing: Haeun Kim)
MBC News awaits your report 24 hours a day.
▷ Phone 02-784-4000
▷ Email [email protected]
▷ KakaoTalk @mbc report